Characteristics and clinical course of primary sclerosing cholangitis in France: A prospective cohort study

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 7, 2010, Pages 842-847

  Garioud, Armand ^a   Seksik, Philippe ^a   Chrétien, Yves ^a   Corphechot, Christophe ^a   Poupon, Raoul ^a   Poupon, Renée Eugénie ^a   Chazouillères, Olivier ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

cholangiocarcinoma; cholestasis; liver transplantation; primary sclerosing cholangitis; ursodeoxycholic acid

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BILE DUCT CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER SURVIVAL; CAUSE OF DEATH; CHOLANGITIS; CHOLECYSTECTOMY; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE COURSE; DRUG MEGADOSE; ENTERITIS; FEMALE; FOLLOW UP; FRANCE; GALLBLADDER CARCINOMA; HUMAN; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER TRANSPLANTATION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PRURITUS; RECURRENT DISEASE; THROMBOCYTE COUNT; TREATMENT OUTCOME; BILE DUCT NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; COLORECTAL NEOPLASMS; DRUG EFFECTS; EPIDEMIOLOGY; GALLBLADDER NEOPLASMS; INCIDENCE; INTRAHEPATIC BILE DUCT; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; CHOLANGITIS, SCLEROSING; COHORT STUDIES; COLORECTAL NEOPLASMS; FEMALE; FRANCE; GALLBLADDER NEOPLASMS; HUMANS; INCIDENCE; LIVER FAILURE; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID; YOUNG ADULT;

EID: 77954012998     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e328331c2b7     Document Type: Article

References (32)

1. Lee YM, Kaplan MM. Primary sclerosing cholangitis. N Engl J Med 1995; 332:924-933.
2. Card TR, Solaymani-Dodaran M, West J. Incidence and mortality of primary sclerosing cholangitis in the UK: a population-based cohort study. J Hepatol 2008; 48:939-944.
3. Broome U, Olsson R, Loof L, Bodemar G, Hultcrantz R, Danielsson A, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut 1996; 38:610-615.
4. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, Rajaram R, Rauws EA, Mulder CJ, et al. Natural history of primary sclerosing cholangitis and prognostic value of cholangiography in a Dutch population. Gut 2002; 51:562-566.
5. Tischendorf JJ, Hecker H, Kruger M, Manns MP, Meier PN. Characterization, outcome, and prognosis in 273 patients with primary sclerosing cholangitis: a single center study. Am J Gastroenterol 2007; 102:107-114.
6. Farrant JM, Hayllar KM, Wilkinson ML, Karani J, Portmann BC, Westaby D, Williams R. Natural history and prognostic variables in primary sclerosing cholangitis. Gastroenterology 1991; 100:1710-1717.
7. Bambha K, Kim WR, Talwalkar J, Torgerson H, Benson JT, Therneau TM, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003; 125:1364-1369.
8. Kim WR, Therneau TM,Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688-694.
9. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables: an Italian multicentre study. The Italian PSC Study Group. Eur J Gastroenterol Hepatol 1996; 8:685-691.
10. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170:2-6; discussion 16-19.
11. Ludwig J. Small-duct primary sclerosing cholangitis. Semin Liver Dis 1991; 11:11-17.
12. Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J Hepatol 1994; 21:787-791.
13. Wiesner RH, Grambsch PM, Dickson ER, Ludwig J, MacCarty RL, Hunter EB, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. Hepatology 1989; 10:430-436.
14. Bergquist A, Said K, Broome U. Changes over a 20-year period in the clinical presentation of primary sclerosing cholangitis in Sweden. Scand J Gastroenterol 2007; 42:88-93.
15. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990; 11:120-123.
16. Beuers U, Spengler U, Kruis W, Aydemir U,Wiebecke B, Heldwein W, et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. Hepatology 1992; 16:707-714.
17. Stiehl A,Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994; 20:57-64.
18. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997; 336:691-695.
19. Olsson R, Boberg KM, de Muckadell OS, Lindgren S, Hultcrantz R, Folvik G, et al. High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005; 129:1464-1472.
20. Mitchell SA, Bansi DS, Hunt N, Von Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001; 121:900-907.
21. Cullen SN, Rust C, Fleming K, Edwards C, Beuers U, Chapman RW. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J Hepatol 2008; 48:792-800.
22. Silveira MG, Lindor KD. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. J Hepatol 2008; 48:692-694.
23. Lindor KD, Kowdley KV, Luketic VAC, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009; 50: (in press).
24. Levy C, Lindor KD. Primary sclerosing cholangitis: epidemiology, natural history, and prognosis. Semin Liver Dis 2006; 26:22-30.
25. Bergquist A, Ekbom A, Olsson R, Kornfeldt D, Loof L, Danielsson A, et al. Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. J Hepatol 2002; 36:321-327.
26. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population-based study. Scand J Gastroenterol 1997; 32:1042-1045.
27. Brandsaeter B, Isoniemi H, Broome U, Olausson M, Backman L, Hansen B, et al. Liver transplantation for primary sclerosing cholangitis; predictors and consequences of hepatobiliary malignancy. J Hepatol 2004; 40:815-822.
28. Burak K, Angulo P, Pasha TM, Egan K, Petz J, Lindor KD. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. Am J Gastroenterol 2004; 99:523-526.
29. Chazouilleres O. Primary sclerosing cholangitis and biliary malignancy: a glimmer of hope? J Hepatol 2004; 40:857-859.
30. Rudolph G, Kloeters-Plachky P, Rost D, Stiehl A. The incidence of cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment with ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2007; 19:487-491.
31. Alpini G, Kanno N, Phinizy JL, Glaser S, Francis H, Taffetani S, LeSage G. Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2 + -, PKC-, and MAPK-dependent pathways. Am J Physiol Gastrointest Liver Physiol 2004; 286:G973-G982.
32. Khare S, Cerda S,Wali RK, von Lintig FC, Tretiakova M, Joseph L, et al. Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer. Cancer Res 2003; 63:3517-3523.